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Lung cancer is the deadliest cancer in developed countries. To reduce its mortality rate, it is 
important to enhance our capability to detect it at earlier stages by developing early diagnostic 
methods. In that context, the analysis of exhaled breath is an interesting approach because of 
the simplicity of the medical act and its non-invasiveness. Thermal desorption comprehensive 
two-dimensional gas chromatography time of flight mass spectrometry (TD-GC×GC-
TOFMS) has been used to characterize and compare the volatile content of human breath of 
lung cancer patients and healthy volunteers. On the sampling side, the contaminations induced 
by the bags membrane and further environmental migration of VOCs during and after the 
sampling have also been investigated. Over a realistic period of 6 h, the concentration of 
contaminants inside the bag can increase from 2 to 3 folds based on simulated breath samples. 
On the data processing side, Fisher ratio (FR) and random forest (RF) approaches were 
applied and compared in regards to their ability to reduce the data dimensionality and to 
extract the significant information. Both approaches allow to efficiently smooth the 
background signal and extract significant features (27 for FR and 17 for RF). Principal 
component analysis (PCA) was used to evaluate the clustering capacity of the different 
models. For both approaches, a separation along PC-1 was obtained with a variance score 
around 35%. The combined model provides a partial separation with a PC-1 score of 52%. 
This proof-of-concept study further confirms the potential of breath analysis for cancer 
detection but also underlines the importance of quality control over the full analytical 















Cancer is one of the major causes of death in Europe and the Western world [1]. 
Although the most prevalent cancers are prostate cancer for men and breast cancer for women 
[1, 2], the highest death rate is observed for lung cancer [3-7]. In 2012, more than 1.6 million 
people died because of lung cancer worldwide [8]. In 2018, for the United States only, lung 
and bronchus cancer deaths are estimated to more than 154,000 [9]. The main cause is the 
lack of specific symptoms of this cancer at the early stage, leading to late stage diagnosis and 
consequent low average 5-years survival rate (<15%) as treatment efficiency decreases with 
the disease progression [10-13]. If lung cancer would be detected early, using alternative 
diagnostic instrumentation for example, the 5-years survival rate could increase from around 
60% and up to 90% [13-17]. Currently, the most common screening method is chest X-ray. 
Other confirmatory methods such as sputum cytology, computer assisted tomography (CT), 
fluorescence bronchoscopy, positron emission tomography (PET), and magnetic resonance 
imaging (MRI) are also used [18-24]. Even if CT helps to detect lung cancer more specifically 
and hence reduces by 20% its mortality [25], this screening method still suffers from 
significant false positive responses. Moreover, those methods are expensive, need experienced 
operating personnel, and expose patients and medical staff to ionizing radiation [26]. Thus, 
there is still a need for the development of alternative screening tests allowing the detection of 
lung cancer at a more curable stage [27].  
Human exhaled breath contains several hundreds of volatile organic compounds (VOCs) 
that can be seen as a fingerprint that could possibly be used to differentiate between 
individuals exhibiting various health status [28]. Breath analysis has shown to be usable to 
highlight possible markers of specific diseases in these individuals [29-34]. Such an approach 
is particularly adapted to potential early diagnosis of cancer because its low level of 














early diagnostic procedure for cancer screening by means of breath analysis could contribute 
to increase the survival rate of diagnosed patients. Breath analysis has several advantages. It is 
non-invasive, it does not require experienced operating personnel to pose medical acts for the 
collection of samples. Furthermore, breath collection is a relatively inexpensive, rapid, 
painless and safe sampling process [19, 33, 35-37]. However, breath analysis has also some 
drawbacks. The very low concentration (from nanomolar to picomolar) of volatile organic 
compounds (VOCs) requires pre-concentration steps (e.g., solid phase microextraction 
(SPME), thermal desorption (TD), purge and trap) to ensure proper analysis of such diluted 
air samples [19, 31, 35, 38]. This is true for mixed expiratory air sampling where total breath 
including dead space air is sampled, resulting in dilution of endogenous VOCs, but also true 
for alveolar air sampling where endogenous VOC concentrations are only 2-3 times higher 
[39]. 
Even when compounds are isolated and reported in the literature, results are rarely 
reproducible and display high dispersion between studies, leading to low reliability of the 
approach. The origin of this issue is partly due to the fact that the essential chemical 
information is hidden under massive amounts of irrelevant signals that make the isolation of 
putative markers of disease from breath a real analytical challenge. Indeed, such irrelevant 
signals are made of significant amounts of endogenous VOCs issued from the basic 
metabolism of the individual and exogenous VOCs related to factors such as food habits, 
hygiene, tobacco consumption, and ambient air [18, 32, 33]. Moreover, other contaminants 
might also come from the materials used during the sampling. Commonly used Tedlar
®
 bags 
are suspected to generate cross contaminations, leaching, and leaking [40]. Phenol and N-N-
dimethyl acetamide are commonly cited in the literature to be the main compounds released 
from those bags [35, 36, 41]. The concentration of the VOCs trapped inside the bags also 














standardization and normalization are the main limitation and ongoing challenges of breath 
analysis [10, 18, 19]. 
To resolve such mixtures of VOCs, the breath content is typically analyzed using gas 
chromatography coupled to mass spectrometry (GC-MS) [18, 31, 43, 44]. Based on such GC-
MS approaches, a limited number of VOCs has been tentatively identified as part of a volatile 
lung cancer profile [19, 31, 43, 45-50]. However, because of the limited peak capacity and 
sensitivity of GC-MS, but also because of the lack of robustness, quality control, and 
validation of sampling and analysis, the approach has not yet found its way to clinical 
application [51]. Peak capacity and sensitivity can be enhanced by using comprehensive two-
dimensional gas chromatography coupled to time-of-flight MS (GC×GC-TOFMS), a known 
efficient separation technique for complex sample analysis [51-53]. Basically, GC×GC relies 
on the use of two different GC phases connected in series via a modulator [54] that, when 
using cryogens to operate, not only enhances the separation power but also provides better 
limits of detection by cryogenic zone compression of chromatographic peaks [55]. When 
coupled to full scan high acquisition speed TOFMS, GC×GC peaks (<200 ms of peak width at 
half height) are accurately described and further deconvoluted in the spectral domain if 
required [56, 57]. Broad dynamic range while allowing mass spectral deconvolution. Proof of 
concept early reports have shown the superiority of GC×GC-TOFMS over GC-MS for the 
separation and identification of VOCs in breath analysis [32, 40, 53, 58-61]. 
With the aim of further supporting the use of GC×GC-TOFMS for breath analysis for 
lung cancer screening, we developed and optimized a TD-GC×GC-TOFMS method based on 
mixed expiratory air sampling. We also studied the importance of control and reliability 
during the sampling of the breath. On the processing side, we investigated a multimodal data 
treatment approach on data sets resulting from the analyses of 29 individuals (15 lung cancer 

















2.1. Patient information  
A total of 29 individuals including 15 lung cancer patients and 14 healthy volunteers 
were included in this study. All subjects were at least 18 years old and they all signed an 
informed consent to participate at this study after being informed about its goals. The study 
was approved by the Ethics Committee of the University of Liège (BECT B707201420493) 
and conducted in conformity with the Declaration of Helsinki. Patients with abnormal chest 
X-rays who were scheduled for bronchoscopy, in addition to age and sex matching controls, 
were sampled using Tedlar
®
 bags of 5 L at the pneumology unit of the university hospital of 
Liège, in Belgium, between January and May 2014 in a series of three sampling campaigns 
(January, March and May). None of the patients had received any form of anticancer therapy 
or medication before the sampling. Prior to the sampling, Tedlar
®
 bags were flushed twice 
with nitrogen (purity >99.99%, Air liquid, BE) to decrease residual contaminants. 
Characteristics of the study population are reported in Table 1. Exhaled breath were 
transferred from the bag to a sorbent tube containing Tenax GR and Carbopack B (Markes 
International Ltd, UK) with a pump at a flow rate of 300 mL/min directly after the sampling 




 bags permeability testing  
12 Tedlar
®
 bags of 1 L were filled with high purity nitrogen. All Bags were placed in a 
box with a saturated atmosphere of toluene, methanol, hexane, and dichloromethane. Every 2 
hours, three bags were pull out the box and the content was transferred onto thermal 

















2.3. Analytical instrumentation and parameters 
Thermal desorption tubes were stored at room temperature (20 °C) before being desorbed 
onto a Unity 2 series thermal desorber (Markes International Ltd.) coupled to a Pegasus 4D 
(LECO, Corp., St. Joseph, MI). The modulator was mounted in an Agilent 7890A gas 
chromatograph equipped with a secondary oven and a quad-jet dual stage modulator working 
with liquid nitrogen as cryofluid [64]. Details regarding the system have been reported 
elsewhere [65]. The column set used was a combination of a Rxi-5Sil (30 m × 0.25 mm i.d x 
0.25 μm df) (Restek Corp., Bellefonte, PA, USA) in the first dimension (1D) and a BPX- 50 
(1.2 m × 0.10 mm i.d x 0.10 μm df) (SGE, Austin, TX, USA) in the second dimension (2D).  
This column combination is classic but offers several advantages for non-targeted screening 
(e.g. structured separation). The use of this classic combination is also useful for study to 
study comparison since, it is the most common used combination. This column set was 
already successfully used in previous VOC mixtures untargeted analysis [63, 66, 67]. During 
the thermal desorption, samples were first purged with dry nitrogen during 1 min to remove 
water. Then, tubes were heated at 300 °C during 5 min and VOCs samples were recollected 
on the general purposed cold trap (Tenax TA/Carbograph 1TD sorbent bed) at -10 °C. 
Samples were injected in the system by heating of the cold trap at 300 °C during 3 min. 
Helium was used as carrier gas with a constant flow rate of 1 mL/min. The main oven had an 
initial temperature of 35 °C during 5 min and then increased until 240°C at a rate of 5 °C/min. 
The temperature offset for the secondary oven was 5 °C above the main oven. The modulation 
period (PM) was 4 s with a hot pulse duration set at 700 ms and a cooling time between stages 














secondary GC oven. 70 eV electron ionization was used. The data acquisition rate was set at a 
frequency of 100 Hz for a mass range from 29 to 450 m/z. Tuning and mass calibration were 
performed daily with perfluorotributylamine (PFTBA). 
2.4. Chromatographic alignment and feature identification 
Data were acquired and processed with the LECO ChromaTOF
®
 4.5 software (LECO 
Corp.). Peak finding, mass deconvolution, integration peak and library searching were 
performed by this software. Mass spectral identification used Wiley (2011) and NIST (2014) 
databases with a match factor threshold >800. Statistical compare option of ChromaTOF
®
 4.5 
software was used to align 2D chromatograms and built a peak table which contains every 
peak found in each samples with a signal to noise ratio of 100 [68, 69]. Peak tables created 
were extracted in .csv files for further data process. 
 
2.5. Multivariate analysis 
Multivariate statistical analyses were conducted using R 3.4.3 using the Rstudio interface 
(Free Software Foundation’s GNU project). All the packages are provided in supplementary 
information. First, all the data were normalized using probabilistic quotient normalization 
(PQN) and log transformed [70]. For specific features detection two approached were 
compared. In an univariate approach, Fisher ratio (FR) calculation was performed in order to 
identify specific compounds differentiating between the two groups [71, 72]. The compounds 
with a FR value above the critical F value (Fcrit) were considered as significant. In a 
multivariate approach, Random Forest algorithm and variable importance ranking were used 
to select the significant features [21]. The resulting data clustering and classification 
efficiency was visualized using principal component analysis (PCA).  
 














3.1. Sample integrity investigation during storage in Tedlar
®
 bag 
It has been reported that the concentration of compounds trapped inside Tedlar
®
 bags 
decreases over time, underlying limitations of the permeability of the membrane and limited 
storage potential  [73]. However, as far as we know, no studies have yet investigated the 
resistance of the bag membrane against outside environmental contaminations. To evaluate 
this effect, 12 Tedlar
®
 bags filled with nitrogen were placed in a box in which the atmosphere 
was saturated in toluene, methanol, hexane, and dichloromethane. Every two hours, three bags 
were pulled out of the box and deflated on TD tubes to be analyzed. The kinetic study 
illustrated in Figure 1 shows how relative intensities of solvents peaks increase as a function 
of time. This time-trend study shows that the relative intensity of each solvent inside the bags 
increased according to the exposure time. The membrane of Tedlar
®
 bag is thus also prone to 
permeation of chemicals from the environment to the bag. It can be concluded that the 
residency time of the sampled breath inside the bags should be kept to a minimum to ensure 
low impact of the sampling procedure on sample integrity. Furthermore, storage conditions 
should carefully be described in studies using such bags. 
 
3.2. Influence of exogenous VOCs during the sampling process 
The TD-GC×GC-TOFMS analysis of the exhaled breath samples of 29 lung cancer 
patients and healthy volunteers, conducted to the detection of an average of 1,078 features for 
each chromatogram. After chromatographic alignment of all samples, the composite peak 
table contained a total of 1,350 robust features. Features screening for chromatographic 
artifacts, multiple peak identifications, and columns bleeding allowed the reduction of the 
data set to 1,019 features. A non-supervised PCA was performed based on this data set and 
the resulting plot can be seen on Figure 2. The visualization of such an unsupervised 














appeared to be related to a sampling period (January, March and April) independently of the 
nature of the samples (patients and controls). This phenomenon demonstrated that the 
influence of the presence of various levels of background of exogenous VOCs during the 
sampling was higher than any possible differences related to the health status of the sampled 
patients, despite the fact that all samples were taken in the same room at the same hospital, 
with the same method, by the same operating staff.  
Different approaches were investigated to smooth the environmental effect on the 
background. A possible approach to reduce the impact of the presence of background 
exogenous VOCs is to perform more complex alveolar air sampling [74]. Having patients 
breathe medical air for lung washout is another option but it is time consuming [9] and our 
own testing in that direction was not conclusive. As shown on the unsupervised dendrogram 
displayed in Fig SI-1, the samples taken from three individuals in three different locations 
with or without medical air washout, does not display any particular clustering. This 
demonstrates that the washout was not able to remove the environment background and do 
not represent a way to go for this study.  
In a second time, data pre-processing and batch effect correction was implemented to 
reduce the impact of exogenous VOCs. Each batch was individually mean-centered in order 
to smooth the impact of the sampling dates (Figure 2 bottom). This step was possible due to 
the parallel sampling between patients and controls. This means that the correction was 
affecting the two classes in the exact same way and it doesn’t generate any overfitting.  The 
corrected data allow to more efficiently extract putative biomarkers from the initial raw data. 
Moreover, it maintains a sampling, which involves spontaneously breathing subjects. 
Following this pre-processing step, two different data processing approaches were 
investigated: 1) a univariate feature selection tool based on Fisher Ratio calculation; 2) a 

















3.3. Univariate feature selection 
The use of Fisher ratio (FR) to select features of interest from biological data sets is 
widely spread among GC×GC non-target studies [62, 71]. Due to the large amount of data 
generated, the supervised FR approach was used to decrease the data dimensionality and 
highlight possible chemical differences between the two classes of samples (lung cancer 
patients versus healthy volunteers) by extracting portions of data where class-to-class 
variations were greater than within-class variations. Furthermore, we applied a critical FR 
cutoff defined for a 1% significance level, in order to even further reduce data dimensionality  
[75]. From the 1,019 features of the cleaned data set, this 1% significance level FR approach 
permitted to extract a list of 27 features (Figure 3). Based on the remaining 27 features, PCA 
and clustering analysis (Figure 4) resulted on a clear separation between lung cancer patients 
and healthy volunteers, without any remaining influence of the sampling period. This 
demonstrates the efficiency of such univariate feature selection approach for the extraction of 
biologically relevant information.  
 
3.4. Multivariate feature selection 
The second statistical approach for feature selection was based on the use of Random 
Forest algorithm (RF), a multivariate machine learning approach build on a decision tree 
approach. Hence, multiple decision trees were created and merged together to obtain a more 
accurate and stable prediction. After the construction of the classification trees, the variables 
were ranked according to their importance and effect on the classification accuracy. The 














mean decrease accuracy. This resulted in the selection of a set of 17 significant features for 
the separation of the two populations. Like for the univariate FR approach, this RF 
demonstrates the potential of this multivariate feature selection approach to properly cluster 
the two populations in the PCA space based on these 17 features (Figure 5).  
 
3.5. Comparison of the feature selection approaches 
The main difference between Random Forest and Fisher Ratio for feature selection is the 
multivariate dimension. Indeed, the combination of decision tree allows performing 
classification based on combined information from different features. Moreover, random 
forest allows obtaining direct classification performance information in addition to the 
feature selection possibilities. Both uni- and multivariate methods allowed to reduce the 
impact of the presence of variable amount of exogenous VOCs related to time of sampling to 
a level that did not significantly interfere anymore with the extraction of biologically relevant 
VOC signatures.  
The 37 features selected by the two approaches were sorted according to their chemical 
family (i.e., alcohol, aldehyde, fatty acid methyl ester (FAME), hydrocarbon, ketone, nitrogen 
containing compounds). From these chemical families, average intensities were calculated 
(Figure 6) and the ratio Patients-intensity on Controls-intensity were evaluated. For FR 
features, the highest ratios were obtained for FAME and ketone compounds. The 
overexpression of these compounds in lung patient samples could be explained by 
inflammation processes inside the lungs. The same family classification process was applied 
to the 17 features highlighted by the random forest approach. Interestingly, the two major 
ratios were also coming from the ketone and the FAME. This observation could indicate that 
the major processes involved in the production of VOCs in the lung of cancer patient could be 














studies and they are supposed to come from oxidative stress reactions. This family based 
approach in non-targeted screening provides insights regarding the general trends of the 
samples, which is already informative. Indeed, for non-targeted studies, the full identification 
of thousands of features is practically impossible, which made the study-to-study comparison 
highly complicated. However, if a group of compounds are found to be specific in different 
studies, it could orient the future research in a predefined group of molecules. 
From the lists of 27 and 17 features, a set of 7 features was common to both approaches 
(Table S1) and would be considered as the most representative markers of differentiation 
between the two classes. As illustrated in Figure 7, a PCA based on these 7 markers results in 
a separation trend between the two classes but the clustering is not as clear as when either FR 
or RF models are applied separately. It can however be noticed that the percentage of 
explained variance (67%) is higher than in both separated models. Even if this PCA is not 
providing extra information, it demonstrates the importance of the technique used for model 
building and the interest of applying different models in order to validate the data processing 
approach. 
Only four of the reported features (both models included) where common to  compounds 
previously reported as a lung cancer human breath biomarker in the literature : Cyclopentane, 
methyl- [76, 77], 2,5-Cyclohexadiene-1,4-dione, 2,6-bis(1,1-dimethylethyl)- [47], 
Hexadecane [50], and eicosane [78]. However, further discussion on compounds 
identification will require identity validation with high resolution detector and standard 
injections. 
 
4. Conclusion  
This work demonstrates the capacity of exhaled breath to discriminate between cancer 
















) bags, the combination of a powerful analytical strategy and a robust 
statistical approach provides good classification performances, overpassing limitations such 
as environmental contamination and sampling variability. It was possible to extract the 
significant information on breath VOC content. The membrane permeability of the sampling 
bags was shown to permit migration of VOCs from the environment to the inside of the bag, 
altering the sample integrity. Moreover, the background suppression effect of medical air 
washout did not provide any reduction of the environmental contamination. Nevertheless, it 
was demonstrated that the influence of the exogenous VOCs could be corrected by using a 
proper pre-processing step.  Finally, two different data analysis strategies (FR and RF) were 
applied to extract significant features. With Both methods, a total of 37 features were detected 
and allow distinguishing the two populations of individuals. Among them, seven features 
were detected by both statistical approaches and allowed to separate the two populations. This 
study underlines the need for analytical controls from sampling to data processing in 
untargeted biological studies. Moreover, the utilization of chemical family profiling could 
represent an alternative to full identification of large data matrix. Confidence in compound 
identifications can be enhanced using high resolution MS and individual standards but was 
out of the scope of the study. The biological interest of the molecules highlighted using our 
approach has to be confirmed by larger cohort studies. 
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Table 1: Characteristics of study subjects 
 Lung cancer patients Healthy volunteers 
Number (%) 15 (52%) 14 (48%) 
Age (year), mean (± SD) 62 ± 7 58 ± 11 
Gender (M/F) 12/3 9/5 
Smoker/ Ex-smoker/ Non-smoker 3/12/0 1/6/7 





















Figure 1.  Kinetic study of the permeability of Tedlar
®
 bag membrane to different solvents. 
 
Figure 2.  Top: Non-supervised PCA score plot with all features detected in the exhaled 
breath of 29 individuals (15 lung cancer patients in red and 14 healthy volunteers in blue). 
Bottom: Non-supervised PCA score plot after individual mean-centering according to the 
batch. Both PCAs were performed on the 1019 features from post pre-processing. 
 
Figure 3. Scheme of the general workflow used for the data treatment and feature selections.  
 
Figure 4.  PCA score plot based on the 27 features extracted by the 1% significance level 
Fisher Ratio approach. The PCA is based on the first two PCs, displaying 44.24% of the total 
variance. 
 
Figure 5.  PCA score plot based on the 17 features extracted by the Random Forest approach. 
The PCA is based on the first two PCs, displaying 45.87% of the total variance. 
 
Figure 6.  Relative chemical family contributions for the selected features isolated fot patients 
and control using both methods (left), Fisher Ratio only (center), Random forest only (right). 
Chemical families: Alcohol (light blue), Aldehyde (orange), FAME (grey), Hydrocarbon 















Figure 7. PCA score plot of the healthy volunteers (negative) and lung cancer patients 
(positive) by using the six features highlight with the Random forest and Fisher Ratio 
















  Fisher ratio and random forest statistical succeed to extract putative markers from 
high dimensional data sets 
 Multimodal statistical approaches allow to identify independent marker-compounds 
 Sample integrity depends on residency time in sampling bag 
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